Patient-derived anti-SARS-CoV-2 recombinant antibodies

Patient-derived anti-SARS-CoV-2 human recombinant antibodies


Antibodies derived from patients are critical reagents in understanding SARS-CoV-2 and COVID-19. In patients who have survived COVID-19, infection elicited an effective antibody response against viral proteins. Recent studies reveal that the receptor binding domain (RBD) of SARS CoV-2 spike protein is a common antigen used by the immune system to generate neutralizing antibodies.

Recombinant genetic technology can be used to isolate and manufacture these antibodies for biomedical uses. Proteintech is partnering with Active Motif to offer an array of recombinant human antibodies against viral spike proteins. These antibodies are developed from genes isolated from B cells of COVID-19 patients. The viral spike protein specific antibody genes were isolated from patient serum, cloned, expressed in HEK293 cells and then subjected to extensive validation in ELISA, Western blotting, and neutralization assays.

SARS-CoV-2 Human recombinant spike antibodies

Catalog number Product name Active Motif clone Applications Species reactivity
91337-PTG SARS-CoV-2 Spike Human Recombinant antibody AM009105 ELISA Virus
91339-PTG SARS-CoV-2 Spike Human Recombinant antibody AM038105 ELISA Virus
91341-PTG SARS-CoV-2 Spike Human Recombinant antibody AM043105 ELISA Virus
91345-PTG SARS-CoV-2 Spike Human Recombinant antibody AM004414 WB, ELISA Virus
91347-PTG SARS-CoV-2 Spike Human Recombinant antibody AM005415 ELISA Virus
91349-PTG SARS-CoV-2 Spike Human Recombinant antibody AM002414 Neutralization, ELISA Virus
91351-PTG SARS-CoV-2 Spike Human Recombinant antibody AM006415 WB, ELISA Virus
91359-PTG SARS-CoV-2 Spike Human Recombinant antibody AM032414 ELISA Virus
91361-PTG SARS-CoV-2 Spike Human Recombinant antibody AM001414 Neutralization, ELISA Virus